Prices delayed by at least 15 minutes | Print

Live UK pricing:

Coiled Therapeutics PLC (COIL)

ORD 1P
Sell: 10.50p|Buy: 12.00p|Change: 0.50 (-4.26%)

Open 

11.75p


Previous close 

11.75p


Trade high 

12.00p


Volume 

1,620,138


Year high 

12.00p


Year low 

6.75p


Dividend yield 


Market capitalisation 

£47.91 mn


P/E ratio 


ISIN 

GB00BSHRN331


Share price

Performance 26/05/2026

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
Coiled Therapeutics PLC- 4.26
More...

Company profile

Coiled Therapeutics PLC is an oncology company engaged in pursuing opportunities to find new therapies for cancer. The product pipeline of the company consists of AO-252, a novel TACC3 inhibitor currently in Phase I clinical trials in the USA; and STAT-6 siRNA programme for immunology indications. The principal activity of the Company is to develop pre-clinical development of next-generation medicines focused on hard-to-treat cancers.

Sector 

Healthcare


News

Recent trades

DateTimePriceQuantityValue (£)
26/05/202604:10:2310.821,9502,370.60
26/05/202604:00:0011.4525,0002,862.50
26/05/202603:12:151110,0001,100.00
26/05/202602:09:0911100,00011,000.00
26/05/202601:59:141150,0005,500.00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.